ReproCELL Incorporated Logo

ReproCELL Incorporated

Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.

4978 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
横浜市港北区新横浜3−8−11
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ReproCELL Incorporated is a global life sciences company providing products and services for preclinical and clinical research, with a focus on stem cell technology, drug discovery, and regenerative medicine. Established in 2003 as a pioneer in the field, the company offers a comprehensive portfolio that supports the entire research workflow. Key offerings include induced pluripotent stem cell (iPSC)-derived human cells, such as neurons and cardiomyocytes, clinical gene editing services, cell culture reagents, and end-to-end discovery platforms for neuroscience and immuno-oncology. ReproCELL serves scientists and pharmaceutical companies worldwide, aiming to accelerate the translation of research into novel therapies and improve human health.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ReproCELL Incorporated and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-26 02:41
Regulatory News Service
内部統制報告書-第23期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-26 02:41
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-26 02:40
Annual Report
有価証券報告書-第23期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-13 07:31
Regulatory News Service
確認書
Japanese 8.1 KB
2024-11-13 07:31
Interim Report
半期報告書-第23期(2024/04/01-2025/03/31)
Japanese 221.1 KB
2024-06-26 03:02
Regulatory News Service
臨時報告書
Japanese 28.0 KB
2024-06-25 07:31
Regulatory News Service
内部統制報告書-第22期(2023/04/01-2024/03/31)
Japanese 22.2 KB
2024-06-25 07:30
Regulatory News Service
確認書
Japanese 8.2 KB
2024-06-25 07:29
Annual Report
有価証券報告書-第22期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-05-23 08:02
Regulatory News Service
臨時報告書
Japanese 20.0 KB
2024-02-09 07:24
Regulatory News Service
確認書
Japanese 8.2 KB
2024-02-09 07:23
Quarterly Report
四半期報告書-第22期第3四半期(2023/10/01-2023/12/31)
Japanese 227.6 KB
2023-11-10 07:05
Quarterly Report
四半期報告書-第22期第2四半期(2023/07/01-2023/09/30)
Japanese 213.2 KB
2023-11-10 07:03
Regulatory News Service
確認書
Japanese 8.1 KB
2023-08-10 08:03
Regulatory News Service
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all ReproCELL Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ReproCELL Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel NRGN
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX

Talk to a Data Expert

Have a question? We'll get back to you promptly.